Corporate Intelligence Profile: Reckitt Benckiser Group PLC
Executive Summary
Reckitt Benckiser Group PLC (Company Number 06270876) is an active public limited company incorporated in June 2007, serving as the ultimate holding entity for a global consumer health and hygiene group. For the accounting year ended 31 December 2024, the consolidated group reported net turnover of £14.17bn, an operating profit of £2.43bn, and net debt of £7.91bn representing 2.0x adjusted EBITDA. The corporate strategy centers on rationalising its portfolio by exiting the non-core Essential Home division by late 2025 and exploring options for Mead Johnson Nutrition, while reallocating capital into core Powerbrands.
Financial Analysis: What the Numbers Show
Evaluating the financial health of a FTSE-listed ultimate parent requires separating standalone parent company filings from full group consolidation. In standalone historical filings, parent entities frequently register minimal operational activity; however, the group's 2024 audited consolidated accounts present substantial scale and gross margin strength.
Revenue Breakdown and Operating Margins
In 2024, the group generated £14,169,000,000 in net revenue, yielding a gross profit of £8,595,000,000. This delivers a gross margin of 60.7%, reflecting high pricing power across its consumer health and hygiene portfolio. Operating profit stood at £2,425,000,000 (17.1% operating margin), while profit before tax reached £2,104,000,000 after net finance costs of £321m (comprising £402m in finance expenses offset by £81m in finance income). Profit after tax totaled £1,428,000,000, following a tax expense of £672,000,000.
| Financial Indicator (Consolidated Group) | FY 2024 | Segment / Metric Contribution |
| :--- | :--- | :--- |
| Turnover (Net Revenue) | £14,169m | Like-for-like growth: +1.4% |
| Cost of Sales | (£5,574m) | Gross Profit: £8,595m (60.7% margin) |
| Operating Profit | £2,425m | Adjusted Operating Profit Growth: +8.6% (CER) |
| Profit Before Tax | £2,104m | Net finance costs: (£321m) |
| Profit After Tax | £1,428m | Effective tax charge: £672m |
| Hygiene Revenue / Margin | £6,140m (43%) | AOP: £1,375m (22.4% margin) |
| Health Revenue / Margin | £5,882m (42%) | AOP: £1,699m (28.9% margin) |
| Nutrition Revenue / Margin | £2,147m (15%) | AOP: £401m (18.7% margin) |
| Net Debt | £7,914m | Leverage ratio: 2.0x adjusted EBITDA |
| Shareholder Distributions | £2,700m | Dividends: £1,381m; Buybacks: £1,300m |
Segmental Performance Metrics
The Group operates across three primary divisions:
1. Hygiene: Contributed £6,140m (43% of group net revenue) with like-for-like growth of 4.2% (volume +1.8%, price/mix +2.4%). Adjusted operating profit was £1,375m, delivering a 22.4% margin. Key performance drivers included expansion in Finish thermoformed tablets (accounting for 75% of tablet revenues) and high single-digit growth in Lysol.
2. Health: Contributed £5,882m (42% of revenue) with like-for-like growth of 2.1%. Non-seasonal health products grew 5.3% on positive volume (+2.5%), whereas seasonal over-the-counter (OTC) brands like Mucinex and Strepsils contracted due to weaker cold and flu incidence. The division delivered £1,699m in adjusted operating profit (28.9% margin).
3. Nutrition: Contributed £2,147m (15% of revenue), registering a 7.3% like-for-like decline. Performance was hindered by a tornado impacting the Mount Vernon manufacturing facility and market share rebasing following prior-year competitor supply issues. The division produced £401m in adjusted operating profit (18.7% margin).
Balance Sheet, Liquidity, and Capital Allocation
Fixed assets were recorded at £2,385,000,000, with goodwill listed at £17,565,000,000. Cash at bank stood at £800,000,000 at year-end. Total net debt increased by £624m during 2024 to reach £7,914,000,000, maintaining balance sheet leverage at 2.0x adjusted EBITDA.
The group maintains committed borrowing facilities totaling £4,450,000,000, of which £124,000,000 was drawn at balance sheet date. A major tranche of £3,500,000,000 in facilities expires after more than two years, and the business remains compliant with all banking covenants. Total capital expenditure for 2024 involved a cash outflow of £465m (2023: £449m). The business recorded a £696m impairment charge on IFCN assets, reflecting altered regulatory standards and required supply network resilience expenditures.
Trade creditors totaled £1,074,000,000, with other debtors standing at £113,000,000. Under its statutory capital allocation framework, the company returned £2.7bn to shareholders in 2024 via £1,381,000,000 in cash dividends (full-year dividend of 202.1p per share, up 5%) and £1.3bn in share buybacks.
Ownership, Leadership, and Governance
Reckitt Benckiser Group PLC is registered at 103-105 Bath Road, Slough, Berkshire, SL1 3UH. The company operates under SIC code 70100 (Activities of head offices). As an active UK public limited company with listed equity, ultimate ownership is widely distributed across institutional shareholders and public market investors.
Governance and Executive Leadership
The Board operates under the standards of the UK Corporate Governance Code. Governance disclosures record key executive transitions:
- Chair: Sir Jeremy Darroch succeeded Chris Sinclair as Chair.
- Chief Executive Officer: Kris Licht, leading the current organizational restructuring.
- Non-Executive Directors: Recent appointments listed in corporate filings include Marybeth Hays, Fiona Dawson, Mahesh Madhavan, and Stefan Oschmann.
Under s.414A Companies Act 2006, the Strategic Report details a transition toward a simplified, area-led structure. Effective January 2025, operations are organized into three geographical reporting areas: Emerging Markets (39% of core revenue), Europe (35%), and North America (26%).
Corporate Social Responsibility and Governance Frameworks
The board oversight structure utilizes a three lines of defense model managed by the Audit Committee and Group Executive Committee. Internal governance policies cover cyber security (aligned with ISO and NIST standards), quality management under the R&D division, and compliance under statutory whistleblowing frameworks.
In accordance with s.172 of the Companies Act 2006, the board conducts stakeholder evaluations through structured engagement with institutional investors, regulatory authorities, and supply chain partners.
Recent Activity, Filings, and Operational Realignment
Corporate filings reveal major structural adjustments aimed at reducing operational overheads and streamlining brand assets.
Strategic Divestments and Portfolio Focus
1. Essential Home Exit: The group has formally classified the Essential Home division as non-core, targeting a complete exit by the end of 2025.
2. Mead Johnson Nutrition Review: Strategic evaluations are underway to determine options for maximizing shareholder value from the Mead Johnson unit.
3. Core Powerbrands: Reallocation of capital to focus strictly on core consumer brands across Self Care, Germ Protection, Household Care, and Intimate Wellness.
'Fuel for Growth' Cost Reduction Program
The group initiated the 'Fuel for Growth' program to streamline corporate layers, automate administrative tasks, and expand shared services. The operational target is to reduce fixed overhead expenses to approximately 19% of net revenue by the end of 2027, reinvesting savings into brand marketing and R&D facilities, including the Wilson facility in North Carolina and the Shanghai innovation center.
Risk Indicators, Liabilities, and What to Watch
For lenders, legal advisers, and corporate counterparties, risk factors detailed in statutory disclosures highlight potential operational vulnerabilities.
+---------------------------------------+
| Group Risk Profile Analysis |
+---------------------------------------+
|
+--------------------------------+-------------------------------+
| | |
v v v
+------------------+ +-------------------+ +------------------+
| Transformation | | Operational & | | Debt Leverage & |
| & Restructuring | | Supply Chain | | Contingencies |
+------------------+ +-------------------+ +------------------+
| Management | | Facility disruption| | Net Debt: £7.91bn|
| retention risk | | (e.g. tornado) | | Borrowing: £4.45b|
| Culture fatigue | | Product safety & | | Regulatory capital|
| Execution errors | | recall exposures | | requirements |
+------------------+ +-------------------+ +------------------+
Concrete Risk Indicators
- Transformation Execution Risk: Large-scale corporate restructuring involves personnel attrition, change fatigue, and execution delay, which could impair short-term delivery during division carve-outs.
- Supply Chain Vulnerabilities: Operational reliance on primary manufacturing hubs exposes the business to localized climate disruptions, as demonstrated by the tornado impact on the Mount Vernon site.
- Product Liability and Regulatory Exposure: Ingestible and topical healthcare products carry inherent exposure to regulatory shifts, quality compliance standards, and product recall liabilities. The £696m IFCN impairment highlights the capital impact of regulatory adjustments.
- Debt Maturity Profile: Net debt of £7.91bn requires ongoing monitoring. While liquidity remains strong (£4.45bn in committed facilities with £124m drawn), credit rating targets rely on maintaining balance sheet leverage at approximately 2.0x EBITDA.
Practical Due Diligence Framework for Large PLCs
When evaluating FTSE-listed parent entities and their subsidiary networks, corporate intelligence professionals should follow a structured verification process:
1. Consolidated vs Standalone Filings: Inspect whether Companies House entries represent the consolidated group accounts or a dormant parent holding company.
2. Charge and Security Verification: Check for fixed and floating charges over corporate assets across subsidiary entities using a company charge check to map institutional lending structures.
3. Insolvency and Litigation Searches: Conduct a formal winding up petition search across group subsidiaries to confirm there are no pending creditor enforcement actions.
4. Gazette Statutory Notice Checks: Monitor The Gazette for notices regarding capital reductions, corporate restructuring, or subsidiary liquidations.
5. Ongoing Monitoring Setup: Establish automated tracking via a free company monitoring system to capture real-time filings, director appointments, and accounts submissions.
Manual Verification vs Automated Intelligence
Completing thorough corporate profiling manually requires pulling annual reports from Companies House, tracking statutory notices via The Gazette, reviewing regulatory releases on the Financial Conduct Authority (FCA) register, and checking High Court cause lists for petition filings.
While manual extraction provides raw primary source documents, it requires aggregating fragmented unstructured text, financial schedules, and subsidiary structures manually. Automated corporate intelligence tools consolidate multi-year accounting extracts, segmental disclosures, and corporate registry events into a single actionable dashboard, enabling deal teams and risk officers to complete initial screening in seconds rather than hours.
You can access the complete public registry record for this entity via the [Reckitt Benckiser Group PLC full corporate record](/company/06270876).
Frequently Asked Questions
What is the registered company number and office address for Reckitt Benckiser Group PLC?
The company number is 06270876. Its registered office is located at 103-105 Bath Road, Slough, Berkshire, SL1 3UH.
What was Reckitt Benckiser Group PLC's net revenue and profit in 2024?
For the year ended 31 December 2024, the group generated consolidated net revenue of £14,169,000,000, an operating profit of £2,425,000,000, and a profit after tax of £1,428,000,000.
What is the group's current debt position?
At 31 December 2024, the group reported net debt of £7,914,000,000, representing a balance sheet leverage ratio of 2.0x adjusted EBITDA. Committed borrowing facilities totaled £4,450,000,000, with £124,000,000 drawn at year-end.
Which business segments are being exited or restructured?
The company plans to exit its non-core Essential Home division by the end of 2025 and is evaluating strategic options for Mead Johnson Nutrition. Future capital focus is centered exclusively on core Powerbrands.
How much capital was returned to shareholders in 2024?
Reckitt returned £2.7bn to shareholders in 2024, comprising £1,381,000,000 in dividends (202.1p total dividend per share) and £1.3bn in share buybacks.
Professional Intelligence Services
For insolvency practitioners, corporate finance advisers, and risk managers performing background checks, keeping pace with statutory filings and risk events across large corporate groups is essential. Use our platform to perform a instant company charge check, search court filings with our winding up petition search, or set up automated alerts using free company monitoring.